361 related articles for article (PubMed ID: 27068338)
21. KRAS mutation: should we test for it, and does it matter?
Roberts PJ; Stinchcombe TE
J Clin Oncol; 2013 Mar; 31(8):1112-21. PubMed ID: 23401440
[TBL] [Abstract][Full Text] [Related]
22. Clinically Viable Gene Expression Assays with Potential for Predicting Benefit from MEK Inhibitors.
Brant R; Sharpe A; Liptrot T; Dry JR; Harrington EA; Barrett JC; Whalley N; Womack C; Smith P; Hodgson DR
Clin Cancer Res; 2017 Mar; 23(6):1471-1480. PubMed ID: 27733477
[No Abstract] [Full Text] [Related]
23. Treatment Rationale and Study Design for the JUNIPER Study: A Randomized Phase III Study of Abemaciclib With Best Supportive Care Versus Erlotinib With Best Supportive Care in Patients With Stage IV Non-Small-Cell Lung Cancer With a Detectable KRAS Mutation Whose Disease Has Progressed After Platinum-Based Chemotherapy.
Goldman JW; Shi P; Reck M; Paz-Ares L; Koustenis A; Hurt KC
Clin Lung Cancer; 2016 Jan; 17(1):80-4. PubMed ID: 26432508
[TBL] [Abstract][Full Text] [Related]
24. Correlation between KRAS mutation status and response to chemotherapy in patients with advanced non-small cell lung cancer☆.
Hames ML; Chen H; Iams W; Aston J; Lovly CM; Horn L
Lung Cancer; 2016 Feb; 92():29-34. PubMed ID: 26775593
[TBL] [Abstract][Full Text] [Related]
25. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L
J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250
[TBL] [Abstract][Full Text] [Related]
26. Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C-Mutant Non-Small Cell Lung Cancer.
Adachi Y; Ito K; Hayashi Y; Kimura R; Tan TZ; Yamaguchi R; Ebi H
Clin Cancer Res; 2020 Nov; 26(22):5962-5973. PubMed ID: 32900796
[TBL] [Abstract][Full Text] [Related]
27. Reliability of EGFR and KRAS mutation analysis on fine-needle aspiration washing in non-small cell lung cancer.
Bozzetti C; Naldi N; Nizzoli R; Azzoni C; Bortesi B; Zobbi V; Bottarelli L; Tiseo M; Gasparro D; Majori M; De Filippo M; Ardizzoni A
Lung Cancer; 2013 Apr; 80(1):35-8. PubMed ID: 23352033
[TBL] [Abstract][Full Text] [Related]
28. The Prognostic Role of KRAS Mutation in Patients with Advanced NSCLC Treated with Second- or Third-line Chemotherapy.
Svaton M; Fiala O; Pesek M; Bortlicek Z; Minarik M; Benesova L; Topolcan O
Anticancer Res; 2016 Mar; 36(3):1077-82. PubMed ID: 26977001
[TBL] [Abstract][Full Text] [Related]
29. KRAS-specific Amino Acid Substitutions are Associated With Different Responses to Chemotherapy in Advanced Non-small-cell Lung Cancer.
Renaud S; Guerrera F; Seitlinger J; Reeb J; Voegeli AC; Legrain M; Mennecier B; Santelmo N; Falcoz PE; Quoix E; Chenard MP; Weingertner N; Beau-Faller M; Massard G
Clin Lung Cancer; 2018 Nov; 19(6):e919-e931. PubMed ID: 30217639
[TBL] [Abstract][Full Text] [Related]
30. Comparison of the prevalence of KRAS-LCS6 polymorphism (rs61764370) within different tumour types (colorectal, breast, non-small cell lung cancer and brain tumours). A study of the Czech population.
Uvirova M; Simova J; Kubova B; Dvorackova N; Tomaskova H; Sedivcova M; Dite P
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Sep; 159(3):466-71. PubMed ID: 26077004
[TBL] [Abstract][Full Text] [Related]
31. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.
Brugger W; Triller N; Blasinska-Morawiec M; Curescu S; Sakalauskas R; Manikhas GM; Mazieres J; Whittom R; Ward C; Mayne K; Trunzer K; Cappuzzo F
J Clin Oncol; 2011 Nov; 29(31):4113-20. PubMed ID: 21969500
[TBL] [Abstract][Full Text] [Related]
32. Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations.
Ludovini V; Bianconi F; Pistola L; Pistola V; Chiari R; Colella R; Bellezza G; Tofanetti FR; Siggillino A; Baldelli E; Flacco A; Giuffrida D; Sidoni A; Crinò L
Cancer Chemother Pharmacol; 2012 May; 69(5):1289-99. PubMed ID: 22302407
[TBL] [Abstract][Full Text] [Related]
33. Analysis of KRAS and BRAF genes mutation in the central nervous system metastases of non-small cell lung cancer.
Nicoś M; Krawczyk P; Jarosz B; Sawicki M; Szumiłło J; Trojanowski T; Milanowski J
Clin Exp Med; 2016 May; 16(2):169-76. PubMed ID: 25902737
[TBL] [Abstract][Full Text] [Related]
34. KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies.
Mao C; Qiu LX; Liao RY; Du FB; Ding H; Yang WC; Li J; Chen Q
Lung Cancer; 2010 Sep; 69(3):272-8. PubMed ID: 20022659
[TBL] [Abstract][Full Text] [Related]
35. Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype.
Metro G; Chiari R; Duranti S; Siggillino A; Fischer MJ; Giannarelli D; Ludovini V; Bennati C; Marcomigni L; Baldi A; Giansanti M; Minotti V; Crinò L
Lung Cancer; 2012 Oct; 78(1):81-6. PubMed ID: 22770374
[TBL] [Abstract][Full Text] [Related]
36. Selumetinib: a promising pharmacologic approach for KRAS-mutant advanced non-small-cell lung cancer.
Metro G; Chiari R; Baldi A; De Angelis V; Minotti V; Crinò L
Future Oncol; 2013 Feb; 9(2):167-77. PubMed ID: 23414467
[TBL] [Abstract][Full Text] [Related]
37. Rare Complex Mutational Profile in an ALK Inhibitor-resistant Non-small Cell Lung Cancer.
Azzato EM; Deshpande C; Aikawa V; Aggarwal C; Alley E; Jacobs B; Morrissette J; Daber R
Anticancer Res; 2015 May; 35(5):3007-12. PubMed ID: 25964588
[TBL] [Abstract][Full Text] [Related]
38. MEK inhibition in non-small cell lung cancer.
Stinchcombe TE; Johnson GL
Lung Cancer; 2014 Nov; 86(2):121-5. PubMed ID: 25257766
[TBL] [Abstract][Full Text] [Related]
39. Does KRAS mutational status predict chemoresistance in advanced non-small cell lung cancer (NSCLC)?
Macerelli M; Caramella C; Faivre L; Besse B; Planchard D; Polo V; Ngo Camus M; Celebic A; Koubi-Pick V; Lacroix L; Pignon JP; Soria JC
Lung Cancer; 2014 Mar; 83(3):383-8. PubMed ID: 24439569
[TBL] [Abstract][Full Text] [Related]
40. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
